Newbury Pharmaceuticals AB Logo

Newbury Pharmaceuticals AB

A hybrid pharmaceutical company focused on specialty drugs in the Nordic region.

NEWBRY | ST

Overview

Corporate Details

ISIN(s):
SE0015244884
LEI:
549300F7XHU3I8CWL373
Country:
Sweden
Address:
Medicon Village, 223 81 Lund

Description

Newbury Pharmaceuticals AB is a hybrid pharmaceutical company focused on specialty prescription drugs and branded medicines. The company's business model combines the capabilities of a marketing authorization holder with those of a specialized commercial partner. It builds its portfolio through global partnerships, in-licensing products, and acting as an exclusive distributor and local representative for other brands. The primary market focus is the Nordic region, with selective international sales. The product portfolio covers various therapeutic areas, including oncology and rare diseases. Newbury Pharmaceuticals manages the full commercialization process, including regulatory affairs, market access, supply chain, and marketing, to deliver medicines to patients and healthcare professionals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2018-10-05 13:14
Edison Investment Research Limited: Edison issues outlook on NeuroVive Pharmace…
English 10.7 KB
2017-06-29 13:30
EQS-News: Edison Investment Research Limited: Edison issues initiation on Neuro…
English 11.1 KB

Automate Your Workflow. Get a real-time feed of all Newbury Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Newbury Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Newbury Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-29 Johan Strömqvist Other Sell 13,564 40,692.00 SEK
2025-04-29 Johan Strömqvist Other Sell 10,400 30,888.00 SEK
2025-04-29 Johan Strömqvist Other Buy 10,200 30,804.00 SEK
2025-04-29 Johan Strömqvist Other Buy 5,000 15,570.50 SEK
2025-04-29 Johan Strömqvist Other Buy 5,000 15,200.00 SEK
2025-04-29 Johan Strömqvist Other Sell 2,436 7,332.36 SEK
2025-04-29 Johan Strömqvist Other Sell 100 305.00 SEK
2024-08-03 Andreas Hedskog Other Buy 200,000 178,000.00 SEK
2024-08-03 Andreas Hedskog Other Other 200,000 N/A
2024-01-22 Alsakali Equity AB Other Buy 4,000 18,920.00 SEK

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.